Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Mölnlycke Health Care reaches 100% renewable electricity target
Mölnlycke, a world leading MedTech company, has secured 100% renewable electricity for all its established and new manufacturing sites and its headquarters, reaching its first near-term SBTi (Science Based Targets initiative)-validated target.
Gothenburg, Sweden. 28 January 2025. “This is a significant milestone in Mölnlycke’s commitment to halving Scope 1 and 2 greenhouse gas emissions by 2030” said Caterina Camerani, VP Sustainability at Mölnlycke. “It propels us towards our vision of building a sustainable healthcare manufacturing ecosystem.”
A major enabler in reaching the goal was signing two virtual Power Purchase Agreements (vPPAs) for the regions where the company has the highest manufacturing footprint. To cover electricity consumption for the sites in the European Union, Mölnlycke signed a long-term vPPA committing to purchasing renewable electricity generated in Mutkalampi, the largest wind farm in Finland. The three manufacturing plants in Malaysia will handle their renewable electricity needs through a similar vPPA from a newly established solar power plant in Bukit Kayu Hitam, Malaysia.
In addition, Mölnlycke continues to invest in on-site generation of solar energy with manufacturing sites in Malaysia and the UK having completed the installation of rooftop solar panels and the installation on factories in Thailand ongoing.
The remaining electricity consumption needs for the established manufacturing sites in Thailand, the UK and the US, as well as the newly established plant in the Kingdom of Saudi Arabia are met through Renewable Energy Certificates (RECs). As stated in the near-term goal validated by SBTi, Mölnlycke will continue active sourcing of renewable electricity through 2030.
For more information, please contact:
Latest news
-
Mölnlycke Health Care breaks ground on $135 million expansion of Wound Care manufacturing facility in Brunswick, Maine
Brunswick, Maine, USA and Gothenburg, Sweden. 23 September 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, today celebrates the groundbreaking of a major expansion to its wound care manufacturing capacity in Brunswick, Maine. This milestone marks the beginning of a $135 million investment aimed at significantly increasing Mölnlycke’s manufacturing capacity in the United States.
-
High burnout among operating room staff poses significant risk to patient safety—new review reveals
Gothenburg, Sweden. 17 September 2025. A new narrative review published in the current issue of Journal of Patient Safety, titled ’Putting Patients at Risk: The Effect of Health Care Provider Burnout on Patient Care in the Operating Room’ reveals alarmingly high levels of burnout among healthcare workers in operating rooms (ORs) and warns of the serious implications for staff well-being, care quality and ultimately patient safety.
-
Filippa Stenberg joins Mölnlycke Board of Directors
-
Mölnlycke awarded second consecutive EcoVadis Platinum medal for sustainability performance
Gothenburg, Sweden. 21 August 2025. Mölnlycke®, a world-leading MedTech company, has once again been recognised as a global sustainability leader, earning the prestigious EcoVadis Platinum medal for the second year in a row.
-
Mölnlycke Health Care expands investment in Tamer Mölnlycke Care joint venture
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.
-
Mölnlycke Health Care agrees to acquire leading wound cleansing manufacturer to consolidate its position as global leader in wound care
Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.
-
EUR bond issue and tender announcement
Mölnlycke intends to issue a new 10-year EUR bond and launches a tender offer for the outstanding EUR 500m bond due February 2025.
-
Mölnlycke signs a EUR 350 million revolving credit facility
On 28 April 2023, Mölnlycke entered into a new EUR 350 million multicurrency revolving credit facility. The facility has a tenor of five years with two one-year extension options and will be used as a backup for general corporate purposes. The facility is a refinancing of the existing and undrawn revolving credit facility signed in 2017.
-
In 2023 Mölnlycke was awarded a gold medal for Sustainability by EcoVadis
The world’s largest and most trusted provider of business sustainability ratings - EcoVadis, has awarded Mölnlycke a gold medal for our focus on sustainability. They have ranked us in the top 3% of companies worldwide.